Back

SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi

McCormack, M. J.; Banda, L.; Kasenda, S.; Hughes, E. C.; Crampin, A. C.; Amoah, A. S.; Read, J. M.; Ho, A.; Willett, B. J.; Hay, J. A.

2026-04-17 infectious diseases
10.64898/2026.04.16.26351029 medRxiv
Show abstract

Serological data provide important insights into SARS-CoV-2 transmission and immunity, particularly in regions with limited routine surveillance such as sub-Saharan Africa. However, antibody waning and boosting following reinfection or vaccination remain poorly characterised, complicating interpretation of serological measurements. Improved understanding of these dynamics is critical for accurate epidemiological inference. Modelling longitudinal serological data provides a means to quantify antibody kinetics and reconstruct infection histories. We analysed 15,679 neutralising antibody (nAb) titres from 1,675 unvaccinated, HIV-uninfected participants in urban (Lilongwe) and rural (Karonga) Malawi (February 2021 - April 2022). NAb titres against ancestral B.1, Beta, Delta, and Omicron (BA.1/BA.2) viruses were measured using an HIV-based SARS-CoV-2 pseudotyped virus neutralisation assay. A multi-level Bayesian model was used to reconstruct infection histories and antibody kinetics. The model identified 429 infections (95% credible interval 417-441), including 39 (9{middle dot}1%) that had not been identified by traditional seroconversion-based thresholds. Antibody levels waned rapidly, with 48% (0{middle dot}403-0{middle dot}560) of the acute boost remaining after three months and only 5% (0{middle dot}027-0{middle dot}098) after one year. Pre-Omicron infections generated stronger antibody boosts than Omicron infections. Responses varied, with individuals clustering into low and high responders. Cross-reactive responses extended across substantial antigenic distances - Omicron infections induced broader immunity. Seroincidence was higher in Lilongwe than in Karonga (0{middle dot}41 vs. 0{middle dot}27 infections per person per three months), driven by the early 2022 Omicron wave. Reinfections were common, particularly among adults and urban residents. SARS-CoV-2 nAb responses following infection were heterogeneous and declined rapidly. This rapid waning underscores the importance of vaccination for sustained protection, while cross-reactivity suggests only partial immunity from prior variants. Identifying reinfections is essential for understanding transmission and finding populations at higher repeat infection risk, particularly where routine surveillance is limited.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Science
429 papers in training set
Top 1%
14.2%
2
Nature Communications
4913 papers in training set
Top 13%
13.8%
3
Nature Microbiology
133 papers in training set
Top 0.1%
9.7%
4
Emerging Infectious Diseases
103 papers in training set
Top 0.1%
8.8%
5
Nature Medicine
117 papers in training set
Top 0.4%
6.1%
50% of probability mass above
6
The Lancet Infectious Diseases
71 papers in training set
Top 0.5%
4.7%
7
eLife
5422 papers in training set
Top 19%
4.7%
8
Nature
575 papers in training set
Top 7%
3.5%
9
Science Translational Medicine
111 papers in training set
Top 1%
3.0%
10
The Lancet Microbe
43 papers in training set
Top 0.4%
2.3%
11
Science Advances
1098 papers in training set
Top 14%
2.0%
12
The Journal of Infectious Diseases
182 papers in training set
Top 2%
1.8%
13
Immunity
58 papers in training set
Top 3%
1.6%
14
PLOS Pathogens
721 papers in training set
Top 6%
1.4%
15
PLOS Biology
408 papers in training set
Top 12%
1.4%
16
Cell
370 papers in training set
Top 13%
1.4%
17
Virus Evolution
140 papers in training set
Top 0.9%
1.3%
18
Cell Host & Microbe
113 papers in training set
Top 4%
1.3%
19
Clinical Infectious Diseases
231 papers in training set
Top 4%
1.2%
20
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 39%
1.2%
21
mBio
750 papers in training set
Top 9%
1.1%
22
eBioMedicine
130 papers in training set
Top 3%
0.9%
23
Scientific Reports
3102 papers in training set
Top 71%
0.9%
24
Nature Genetics
240 papers in training set
Top 8%
0.7%
25
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
26
Epidemics
104 papers in training set
Top 2%
0.7%
27
JCI Insight
241 papers in training set
Top 9%
0.6%
28
Journal of Experimental Medicine
106 papers in training set
Top 5%
0.6%
29
PLOS Medicine
98 papers in training set
Top 5%
0.6%